Original articleType 2 diabetes mellitus in France in 2012: Results from the ObEpi survey
Introduction
The global prevalence of diabetes has seen a constant increase over recent decades. The number of people worldwide with the disorder has almost doubled, from 153 million in 1980 to 347 million in 2008 [1]. In 2011, diabetes became the leading long-term disease in France, with 1,885,382 cases, exceeding the 1,861,113 cases of cancers. This was the largest increase seen in 2010 (+6.5%), ahead of that for cardiovascular diseases (+5.3%) [2].
The vast majority of cases of diabetes mellitus are type 2 (T2DM). This is a result of the increasing prevalence of obesity [3], [4], [5] due to changes in lifestyle [6] and diet [7]. A sound understanding of the epidemiology of T2DM is therefore required, as this metabolic disorder can benefit from public policies of prevention.
Different approaches have been used to provide regular updates of the prevalence of diabetes, with analyses of its comorbidities and context of evolution. The public-health dimension of the disease has been the main concern of several campaigns in France conducted by the national health insurance fund (Caisse primaire d’assurance maladie des travailleurs salariés, CNAMTS) [8], [9], [10]. A number of epidemiological studies have addressed different issues, such as quality of care and management of associated cardiovascular risks [11], complications of diabetes [12], and patients’ perception of the disease and its impact on daily life [13].
The obesity epidemiology (ObEpi) surveys comprise six datasets recording the prevalence of obesity in the French population between 1997 and 2012. The data were collected every 3 years using the same methodology. In the ObEpi 2012 survey, the questionnaire included new questions regarding ongoing treatments for cardiovascular disease, dyslipidaemia and diabetes, and revealed that the prevalence of known T2DM is 2.2% in people of normal weight, 6.9% in overweight people and 16.0% in the obese population [14]. Detailed analyses of these data for the treatment of diabetes is of interest in light of the recent position statement of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) [15].
The primary objective of the present analysis was to estimate the prevalence of known T2DM in the general adult French population. Secondary objectives were to describe the associated comorbidities, treatments and sociodemographic factors related to the disease.
Section snippets
Methods
The ObEpi epidemiological surveys evaluated the prevalence of overweight and obesity in the French population every 3 years since 1997. The present analysis describes the population participating in the ObEpi 2012 survey (conducted in France between January and March 2012) that was treated for T2DM with hygiene and dietary measures and/or medical treatment.
Prevalence of T2DM
Of the 25,714 respondents aged ≥ 18 years, 1486 (5.8%; 95% CI: 5.5–6.1) reported ongoing treatment for diabetes (although treatment data for 135 people were not documented). This represents an estimated 2,860,000 cases of diabetes in France when extrapolated to the entire French population aged ≥ 18 years, according to the official 2010 French population data [17]. T1DM was reported by 71 individuals (4.8% of diabetes patients) and T2DM by 1415 respondents, corresponding to 95.2% of all diabetes
Discussion
This ObEpi survey estimated a prevalence of 5.8% for diabetes and 5.5% for known T2DM in 2012 in France; it also provided a description of the associated comorbidities, ongoing treatments and sociodemographic characteristics of the population with T2DM.
The prevalence estimated in the present analysis is in line with the most recently published data [18]. Reported prevalence rates for treated diabetes were 4.6% in 2006 [19], 3.95% in 2007 [20] and 4.4% in 2009 [10] for all types of diabetes.
Disclosure of interest
E. Eschwege: member of advisory board and speaker engagements for Novo Nordisk, Novartis and Roche. Consultation for the Institut national de Veille Sanitaire (National Institute of Public Health Surveillance) HAS/Commission de la transparence (Transparency Commission)/Groupe d’intérêt de santé publique (Public Health Interest Group).
A. Basdevant was a member of the advisory board for the ObEpi surveys for Roche; he received no remuneration.
Christine Moisan, MD, was an employee of Roche at the
Acknowledgements
The ObEpi surveys have been made possible thanks to the institutional support and funding of Roche SAS.
Funding: Medical writing assistance was provided by Potentiel d’Action (Olivier Galut, Isabelle Lawrence) and funded by Roche.
References (32)
- et al.
National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants
Lancet
(2011) - et al.
The built environment and obesity: a systematic review of the epidemiologic evidence
Health Place
(2010) - et al.
Risk factors for overweight and obesity in French adolescents: physical activity, sedentary behaviour and parental characteristics
Nutrition
(2010) - et al.
A western-like fat diet is sufficient to induce a gradual enhancement in fat mass over generations
J Lipid Res
(2010) - et al.
Prevalence of diagnosed type 2 diabetes mellitus in the French general population: the INSTANT study
Diabetes Metab
(2009) - et al.
How do patients with type 2 diabetes perceive their disease? Insights from the French DIABASIS survey
Diabetes Metab
(2009) - et al.
Gender differences in insulin resistance, body composition, and energy balance
Gend Med
(2009) - et al.
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Lancet
(2006) Proposition de l’assurance maladie sur les charges et produits pour l’année 2012
(2011)- et al.
Evolution of obesity prevalence in France: an age-period cohort analysis
Epidemiology
(2010)
The levelling off of the obesity epidemic since the year 1999 - a review of evidence and perspectives
Obes Rev
Epidemiology of diabetes in metropolitan France
Diabetes Metab
Échelon national du service médical. Département analyse des soins de ville et hospitaliers
Diabète traité : quelles évolutions entre 2000 et 2009 en France ?
Bull Epidemiol Hebd
Caractéristiques, risque vasculaire et complications chez les personnes diabétiques en France métropolitaine : d’importantes évolutions entre Entred 2001 et Entred 2007
Bull Epidemiol Hebd
AFERO 2013 29e réunion de l’AFERO, Paris, 17–18 janvier 2013, Centre de recherche des Cordeliers, 75006 Paris, France. Abstract 39, évolution de l’obésité en France : résultats de l’enquête ObÉpi 2012
Obesite
Cited by (37)
Particularities of diabetes mellitus in geriatrics in Senegal
2023, NPG Neurologie - Psychiatrie - GeriatrieDescription of basal insulin therapy practices in type 2 diabetes in general medicine in France: The PRACTISULINE® study
2022, Medecine des Maladies MetaboliquesMedium term post-bariatric surgery deficit of vitamin B12 is predicted by deficit at time of surgery
2021, Clinical NutritionCitation Excerpt :In the last decades, obesity has become a global health issue that affects 600 million people worldwide [1]. In France, the prevalence of obesity is estimated at 17% [2]. To date, bariatric surgery (BS) represents the gold standard in treating patients with morbid obesity when lifestyle interventions such as diet, physical activity, behavior therapy and pharmacotherapy fail [3].
Impact of sex and glucose-lowering treatments on hypoglycaemic symptoms in people with type 2 diabetes and chronic kidney disease. The French Chronic Kidney Disease – Renal Epidemiology and Information Network (CKD-REIN) Study
2019, Diabetes and MetabolismCitation Excerpt :Other studies indicate that insulin treatment is more frequent in women with type 2 diabetes, albeit not to the same extent as in our study [25–27]. For people with type 2 diabetes in the ObEpi study from the general French population, 8.3% of women were morbidly obese (BMI ≥ 40 kg/m2), 3.4% of men [28]; the corresponding prevalences in CKD-REIN patients were much higher, 20% and 6.5% respectively. The average age in ObEpi was 66 years, a little younger than in CKD-REIN, with a shorter duration of diabetes.
Triglycerides and glycated hemoglobin for screening insulin resistance in obese patients
2018, Clinical Biochemistry